Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

By on    Pharma Industry News  

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.

Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. This marks Dupixent as the first biologic medication approved for patients who have not responded adequately to traditional topical prescription treatments […]

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

By on    Pharma Industry News  

The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase 3 clinical trial for adults with uncontrolled moderate-to-severe atopic dermatitis (AD). Breakthrough in Atopic Dermatitis Treatment The CHRONOS trial, a critical phase 3 study, involved Dupixent administered alongside topical corticosteroids […]